Martha Trela has joined Affymetrix in a sales and marketing position. She comes to Affymetrix from Applied Biosystems, where she was vice president for worldwide marketing programs and communications.
Trevor Nicholls has become a member of the European business development team of Affymetrix, the company said in an SEC filing last week. He used to be Affymetrix’s executive vice president for product marketing and development.
Timothy Mayleben has joined the board of directors of Rubicon Genomics, replacing Richard Sloan, the Ann Arbor, Mich.-based company said today. Most recently, he was COO and CFO of Esperion Therapeutics, which was recently acquired by Pfizer.
Robert Saltmarsh has been promoted to chief financial officer of Nanogen, the San Diego-based company said last week. He joined Nanogen as vice president of corporate development in September. Most recently, he was a consultant for several startup companies and taught entrepreneurial finance at the University of California at Riverside. Saltmarsh holds a BA in economics and an MBA in finance from the University of Michigan.
Charles Craig has become president of the Georgia Biomedical Partnership, the industry organization said last week. He is the first full-time president of GBP. Previously, Craig was director of publications for the Biotechnology Industry Organization. He holds a Master’s degree in journalism from Louisiana State University and a BA from the University of Virginia.
Burrill & Co. has made a number of staff changes, the merchant bank said last week. Giovanni Ferrara, Richard Haiduck, and James Watson became managing directors; Bryant Fong has become principal; Stephen Kujawa has become director; and David Haselwood and Rizwan Velji have become senior associates. The company appointed Ann Hanham, John Kim, Roger Wyse, Mike Ullman, John Haag, and Tim Young as general partners of the Burrill Life Sciences Capital Fund III.